{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-024838","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.914106+00:00","generated_at":"2026-05-26T22:58:10.081043+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study","bullets":["Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.","Combined price $26.0825 per share/warrant; warrants exercisable at $26.02, expire Feb 13, 2032; pre-funded warrants at $0.0001.","Net proceeds to fund ALG-000184 Phase 2 study in chronic hepatitis B; cash runway extended into H2 2026.","Placement led by life sciences investor; Jefferies and Piper Sandler as agents; lead investor gets board nomination rights.","Company to file resale registration statement within 45 days; securities sold in private placement exempt from registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-024838","json":"https://secwatch.observer/filing/0001193125-25-024838.json","markdown":"https://secwatch.observer/filing/0001193125-25-024838.md","text":"https://secwatch.observer/filing/0001193125-25-024838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312525024838/0001193125-25-024838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312525024838/d901857d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:58:10.081043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}